NCT03292016View on ClinicalTrials.gov

"A Study That Compares the Extent to Which Apomorphine Becomes Available in the Body After Taking Either an Investigational Drug Containing Apomorphine or Apomorphine That is Injected Under the Skin in People With PD Complicated by OFF Episodes"

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 22, 2017

Primary Completion Date

March 5, 2019

Study Completion Date

March 5, 2019

Conditions

Parkinson Disease

Interventions

DRUG

APL-130277

APL-130277 sublingual thin film

DRUG

APO-go

Subcutaneous APO-go

DRUG

Apokyn

Subcutaneous APOKYN

Trial Locations (3)

33486

Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton

33980

Parkinson's Disese Treatment Center of SW Florida, Port Charlotte

48334

QUEST Research Institute, Farmington Hills

All Listed Sponsors

lead

Sumitomo Pharma America, Inc.

INDUSTRY

NCT03292016 - "A Study That Compares the Extent to Which Apomorphine Becomes Available in the Body After Taking Either an Investigational Drug Containing Apomorphine or Apomorphine That is Injected Under the Skin in People With PD Complicated by OFF Episodes" | Biotech Hunter | Biotech Hunter